- Home
- BQ vs MYNZ Comparison
BQ vs MYNZ Comparison
Compare BQ & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- MYNZ
- Stock Information
- Founded
- BQ 2008
- MYNZ 2021
- Country
- BQ China
- MYNZ Germany
- Employees
- BQ N/A
- MYNZ N/A
- Industry
- BQ Other Specialty Stores
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- MYNZ Health Care
- Exchange
- BQ Nasdaq
- MYNZ Nasdaq
- Market Cap
- BQ 7.1M
- MYNZ 7.9M
- IPO Year
- BQ 2020
- MYNZ 2021
- Fundamental
- Price
- BQ $3.30
- MYNZ $1.60
- Analyst Decision
- BQ
- MYNZ Buy
- Analyst Count
- BQ 0
- MYNZ 2
- Target Price
- BQ N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- BQ 39.8K
- MYNZ 67.8K
- Earning Date
- BQ 10-28-2025
- MYNZ 10-21-2025
- Dividend Yield
- BQ N/A
- MYNZ N/A
- EPS Growth
- BQ N/A
- MYNZ N/A
- EPS
- BQ N/A
- MYNZ N/A
- Revenue
- BQ $64,617,102.00
- MYNZ $893,991.00
- Revenue This Year
- BQ N/A
- MYNZ $26.06
- Revenue Next Year
- BQ N/A
- MYNZ $4.97
- P/E Ratio
- BQ N/A
- MYNZ N/A
- Revenue Growth
- BQ N/A
- MYNZ N/A
- 52 Week Low
- BQ $1.62
- MYNZ $1.30
- 52 Week High
- BQ $9.89
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- BQ 57.55
- MYNZ 44.52
- Support Level
- BQ $2.88
- MYNZ $1.56
- Resistance Level
- BQ $3.86
- MYNZ $1.79
- Average True Range (ATR)
- BQ 0.36
- MYNZ 0.10
- MACD
- BQ 0.01
- MYNZ -0.01
- Stochastic Oscillator
- BQ 52.94
- MYNZ 18.80
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.